{"contentid": 488253, "importid": NaN, "name": "FDA approves Qelbree to treat ADHD", "introduction": "The US Food and Drug Administration has approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients six to 17 years of age.", "content": "<p>Supernus Pharmaceuticals (Nasdaq: SUPN) saw its shares rise 7.2% to $26.72 in pre-market trading today, after the US biotech late on Friday announced that the US Food and Drug Administration has approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients six to 17 years of age.</p>\n<p>This was a welcome development for Supernus, which in November last year received a Complete Response Letter (CRL) for SPN-812 (viloxazine hydrochloride; SPN-812) from the FDA, for the treatment of children with ADHD.</p>\n<p>The agency primarily raised concerns over Supernus&rsquo; in-house laboratory, which the firm said &ldquo;recently moved to a new location.&rdquo; Prior to that, the firm received a Refusal to File (RTF) letter from the FDA regarding its submission for this candidate.</p>\n<h2><strong>A not controlled substance with proven efficacy</strong></h2>\n<p>&ldquo;Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD,&rdquo; said Jack Khattar, president and chief executive of Supernus, adding: &ldquo;Qelbree provides prescribing physicians and patients living with ADHD a therapy that is not a controlled substance with proven efficacy and a tolerable safety profile. We are grateful to the patients, families and their care givers who participated in and supported our research.&rdquo;</p>\n<p>&ldquo;ADHD is one of the most common mental health issues in the US,&rdquo; said Dr Andrew Cutler, Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University, and chief medical officer, Neuroscience Education Institute. &ldquo;The right treatment is key for children and adolescents, as they grow and navigate school and social relationships. This approval offers a novel once a day sprinkleable non-stimulant that can be a great option for children and adolescents with ADHD.&rdquo;</p>\n<p>The approval of Qelbree is supported by data from an extensive development program consisting of four Phase III clinical trials that studied more than 1000 pediatric patients from the age of six to 17 years.</p>\n<p>In December 2020, the company announced positive results from a Phase III trial in adult patients with ADHD and plans to submit a supplemental New Drug Application to the FDA for Qelbree in adults in the second half of 2021.</p>", "date": "2021-04-06 10:23:00", "meta_title": "FDA approves Qelbree to treat ADHD", "meta_keywords": "Supernus Pharmaceuticals, Qelbree, Viloxazine, \nADHD, Pediatric, FDA, Approval", "meta_description": "FDA approves Qelbree to treat ADHD", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-05 14:58:42", "updated": "2021-04-06 10:23:59", "access": NaN, "url": "https://www.thepharmaletter.com/article/fda-approves-qelbree-to-treat-adhd", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "supernus_pharmaceuticals_company.jpg", "image2id": "fda_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "ADHD", "sector_tag": "Biotechnology", "therapy area_tag": "CNS Diseases, Neurological", "topic_tag": "Focus On, One to Watch Companies, Regulation, US FDA", "geography_tag": "USA", "company_tag": "Supernus Pharmaceuticals", "drug_tag": "Qelbree, SPN-812, viloxazine", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-06 10:23:00"}